Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Comment by Investor62on Jul 26, 2020 12:38pm
117 Views
Post# 31320816

RE:$1.5 billion in federal stimulus for testing technology

RE:$1.5 billion in federal stimulus for testing technologyfor me is unclear why they should get some grant money. I hope as this will avoid another financing which would not be in the actual shareholder interest except, they let us participate.
Regarding dates - I think Jack mentioned some connection to Washington. More of interest for me is the part of dating (takeover) - you can listen this in the webcast (https://www.youtube.com/watch?v=q2JGHLDhWN4)
Interesting is a statement from Jack at around 1:55 where he explained their intention for the dating. This can be a vertical licensing, straight acquisition or a revenue share partnership in helping to manufacture and distribution when the time is right (my personal assumption: he knows the value of the company and is not interested in the quick cash). GenMark (GNMK - https://www.genmarkdx.com/) 1,25B with a margin of 28 % with a cost of the cartridge about $ 50 so they cannot go into the food safety or the open access markets which is huge for Lexagene.
Jack admitted that GenMark is selling and FDA approved – both still missing for Lexagene, but he is optimistic to get to marketed with FDA approval by September 2020. I do not think that he will accept any offering at a level of GenMark
<< Previous
Bullboard Posts
Next >>